Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma

Hatsuyo Takaoka; Hideki Terai; Katsura Emoto; Lisa Shigematsu; Fumimaro Ito; Ayaka Saito; Masahiko Okada; Keiko Ohgino; Shinnosuke Ikemura; Hiroyuki Yasuda; Ichiro Nakachi; Ichiro Kawada; Koichi Fukunaga; Kenzo Soejima

doi:10.2147/OTT.S375959

Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma

Hatsuyo Takaoka, Hideki Terai, Katsura Emoto, Lisa Shigematsu, Fumimaro Ito, Ayaka Saito, Masahiko Okada, Keiko Ohgino, Shinnosuke Ikemura, Hiroyuki Yasuda, Ichiro Nakachi, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima

Research output: Contribution to journal › Article › peer-review

Abstract

We report the first case of a patient with non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) who achieved disease-and treatment-free survival for nearly 10 years. A 50-year-old man was diagnosed with NSCLC with MPE and underwent chemotherapy and salvage thoracic surgery. The patient received chemotherapy with cisplatin, pemetrexed, and bevacizumab, and a partial response was achieved. After informed consent was obtained from the patient, right middle lobectomy was performed to achieve local tumor control. Postoperative adjuvant chemotherapy with pemetrexed and bevacizumab was discontinued after almost 1 year of chemotherapy due to side effects such as diarrhea and muscle weakness. The patient has survived without recurrence of lung cancer for more than 11 years after being diagnosed and nearly 10 years after discontinuing chemotherapy.

Original language	English
Pages (from-to)	981-989
Number of pages	9
Journal	OncoTargets and Therapy
Volume	15
DOIs	https://doi.org/10.2147/OTT.S375959
Publication status	Published - 2022

Keywords

bevacizumab
cure
malignant pleural effusion
pemetrexed
salvage surgery

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/OTT.S375959

Cite this

@article{a4b9e9a0cbb74ae58a6ecfa757213d85,

title = "Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma",

abstract = "We report the first case of a patient with non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) who achieved disease-and treatment-free survival for nearly 10 years. A 50-year-old man was diagnosed with NSCLC with MPE and underwent chemotherapy and salvage thoracic surgery. The patient received chemotherapy with cisplatin, pemetrexed, and bevacizumab, and a partial response was achieved. After informed consent was obtained from the patient, right middle lobectomy was performed to achieve local tumor control. Postoperative adjuvant chemotherapy with pemetrexed and bevacizumab was discontinued after almost 1 year of chemotherapy due to side effects such as diarrhea and muscle weakness. The patient has survived without recurrence of lung cancer for more than 11 years after being diagnosed and nearly 10 years after discontinuing chemotherapy.",

keywords = "bevacizumab, cure, malignant pleural effusion, pemetrexed, salvage surgery",

author = "Hatsuyo Takaoka and Hideki Terai and Katsura Emoto and Lisa Shigematsu and Fumimaro Ito and Ayaka Saito and Masahiko Okada and Keiko Ohgino and Shinnosuke Ikemura and Hiroyuki Yasuda and Ichiro Nakachi and Ichiro Kawada and Koichi Fukunaga and Kenzo Soejima",

note = "Funding Information: This work was supported in part by the Japan Society for the Promotion of Science to H.T. 22K08289. Publisher Copyright: {\textcopyright} 2022 Takaoka et al.",

year = "2022",

doi = "10.2147/OTT.S375959",

language = "English",

volume = "15",

pages = "981--989",

journal = "OncoTargets and Therapy",

issn = "1178-6930",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma

AU - Takaoka, Hatsuyo

AU - Terai, Hideki

AU - Emoto, Katsura

AU - Shigematsu, Lisa

AU - Ito, Fumimaro

AU - Saito, Ayaka

AU - Okada, Masahiko

AU - Ohgino, Keiko

AU - Ikemura, Shinnosuke

AU - Yasuda, Hiroyuki

AU - Nakachi, Ichiro

AU - Kawada, Ichiro

AU - Fukunaga, Koichi

AU - Soejima, Kenzo

PY - 2022

Y1 - 2022

N2 - We report the first case of a patient with non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) who achieved disease-and treatment-free survival for nearly 10 years. A 50-year-old man was diagnosed with NSCLC with MPE and underwent chemotherapy and salvage thoracic surgery. The patient received chemotherapy with cisplatin, pemetrexed, and bevacizumab, and a partial response was achieved. After informed consent was obtained from the patient, right middle lobectomy was performed to achieve local tumor control. Postoperative adjuvant chemotherapy with pemetrexed and bevacizumab was discontinued after almost 1 year of chemotherapy due to side effects such as diarrhea and muscle weakness. The patient has survived without recurrence of lung cancer for more than 11 years after being diagnosed and nearly 10 years after discontinuing chemotherapy.

AB - We report the first case of a patient with non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) who achieved disease-and treatment-free survival for nearly 10 years. A 50-year-old man was diagnosed with NSCLC with MPE and underwent chemotherapy and salvage thoracic surgery. The patient received chemotherapy with cisplatin, pemetrexed, and bevacizumab, and a partial response was achieved. After informed consent was obtained from the patient, right middle lobectomy was performed to achieve local tumor control. Postoperative adjuvant chemotherapy with pemetrexed and bevacizumab was discontinued after almost 1 year of chemotherapy due to side effects such as diarrhea and muscle weakness. The patient has survived without recurrence of lung cancer for more than 11 years after being diagnosed and nearly 10 years after discontinuing chemotherapy.

KW - bevacizumab

KW - cure

KW - malignant pleural effusion

KW - pemetrexed

KW - salvage surgery

UR - http://www.scopus.com/inward/record.url?scp=85138168877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138168877&partnerID=8YFLogxK

U2 - 10.2147/OTT.S375959

DO - 10.2147/OTT.S375959

M3 - Article

AN - SCOPUS:85138168877

SN - 1178-6930

VL - 15

SP - 981

EP - 989

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

ER -

Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this